Literatur
- 1
Ardeshna K M, Smith P, Norton A. et al .
Long-term effect of a watch and wait policy versus immediate systemic treatment for
asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
Lancet.
2003;
362
516-522
- 2
Bosch F, Perales M, Cobo F. et al .
Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed
chronic lymphocytic leukemia or follicular lymphoma (abstract).
Blood.
1997;
90
(Suppl 1)
2360
- 3
Cartron G, Watier H, Golay J, Solal-Celigny P.
From the bench to the bedside: ways to improve rituximab efficacy.
Blood.
2004;
104
2635-2642
- 4
Cheson B D.
Radioimmunotherapy of non-Hodgkin lymphomas.
Blood.
2003;
101
391-398
- 5
Cohen Y, Solal-Celigny P, Polliack A.
Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy
as primary treatment, treatment for relapsed disease, re-treatment and maintenance.
Haematologica.
2003;
88
811-823
- 6
Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P. et al .
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients
with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Blood.
2001;
97
101-106
- 7
Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J.
Prolonged clinical and molecular remission in patients with low-grade or follicular
non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
J Clin Oncol.
2004;
22
4711-4716
- 8
Deconinck E, Foussard C, Milpied N. et al .
High dose therapy followed by autologous purged stem cell transplantation and doxorubicin
based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter
study by the GOELAMS.
Blood.
2005;
105
3817-3823
- 9
Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F,
Rothmann F, Rohrberg R, Böck H P, Wandt H, Unterhalt M, Hiddemann W.
The Addition of Rituximab to a Combination of Fludarabine, Cyclophosphamide, Mitoxantrone
(FCM) significantly increases the Response Rate and prolongs Survival as compared
to FCM alone in Patients with Relapsed and Refractory Follicular and Mantle Cell Lymphomas
- Results of a Prospective Randomized Study of the German Low Grade Lymphoma Study
Group (GLSG).
Blood.
2004;
104
3064-3071
- 10
Gordon L I, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C,
Pohlman B, Bartlett N, Wiseman G, Darif M, White C.
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response
rates and durable remissions in patients with previously treated B-cell lymphoma.
Clin Lymphoma.
2004;
5
98-101
- 11
Ghielmini M, Schmitz S F, Cogliatti S B, Pichert G, Hummerjohann J. et al .
Prolonged treatment with rituximab in patients with follicular lymphoma significantly
increases event-free survival and response duration compared with the standard weekly
x 4 schedule.
Blood.
2004;
103
4416-4423
- 12
Hainsworth J D, Litchy S, Shaffer D W, Lackey V L, Grimaldi M, Greco F A.
Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment
at progression in patients with indolent non-Hodgkin’s lymphoma - a randomized phase
II trial of the Minnie Pearl Cancer Research Network.
J Clin Oncol.
2005;
23
1088-1095
- 13
Herold M, Pasold R, Srock S. et al .
Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab
Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone
in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma
(MCL).
Blood.
2004;
104
(Suppl 1)
584a
- 14
Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B,
Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis H -E, Freund M, Wörmann B,
Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R,
Unterhalt M.
Front-line therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin,
vincristine and prednisone (CHOP) significantly improves the outcome of patients with
advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective
randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Blood.
2005;
(in press)
- 15
Horning S J.
Natural history of and therapy for the indolent non-Hodgkin’s lymphomas.
Semin Oncol.
1993;
20
(Suppl 5)
75-88
- 16 Jaffe E S, Harris N L, Stein H, Vardiman J. World Health Organisation Classification
of Tumours: Tumours of the Haemopoitic and Lymphoid Tissues. IARC Press, Lyon 2001
- 17
Khouri I F, Saliba R M, Giralt S A. et al .
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for
indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and
treatment-related mortality.
Blood.
2001;
98
3595-3599
- 18
Klasa R J, Meyer R M, Shustik C. et al .
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine
and prednisone in patients with recurrent low-grade non-Hodgkin`s lymphoma previously
treated with an alkylating agent or alkylatr-containing regimen.
J Clin Oncol.
2002;
20
4649-4654
- 19
Korsmeyer S J.
BCL-2 gene family and the regulation of programmed cell death.
Cancer Res.
1999;
(Suppl)
1693s-1700s
- 20
Lenz G, Dreyling M, Schiegnitz E. et al .
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in
first remission prolongs progression-free survival in follicular lymphoma: results
of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
Blood.
2004;
104
2667-2674
- 21
Lenz G, Dreyling M, Schiegnitz E. et al .
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy
and autologous stem-cell transplantation in patients with indolent lymphoma: results
of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
J Clin Oncol.
2004;
22
4926-4933
- 22
Marcus R, Imrie K, Belch A. et al .
CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced
follicular lymphoma.
Blood.
2005;
105
1417-1423
- 23
McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S. et al .
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:
half of patients respond to a four-dose treatment program.
J Clin Oncol.
1998;
16
2825-2833
- 24
Nickenig C, Dreyling M, Schiegnitz E. et al .
CHOP Inproves Response Rates but Not Overall Survival in Follicular and Mantle Cell
Lymphoma (MCL) - Results of a Randomized Trail of the German Low Grade Lymphoma Study
Group (GLSG). Annual Meeting of the American Society of Hematology, San Diego (Abstract).
Blood.
2004;
104
(Suppl 1)
611
- 25
O’Connor O A, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M,
Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J,
Schenkein D, Zelenetz A D.
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients
with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma.
J Clin Oncol.
2005;
23
676-684
- 26
Ott G, Katzenberger T, Lohr A, Kindelberger S, Rudiger T, Wilhelm M, Kalla J, Rosenwald A,
Muller J G, Ott M M, Muller-Hermelink H K.
Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma:
2 types of follicular lymphoma grade 3.
Blood.
2002;
99
3806-3812
- 27
Ramanarayanan J, Hernandez-Ilizaliturri F J, Czuczman M.
In vivo downregulation of bcl-2 by G3139 (G) enhances Rituximab anti-tumor activity:
effect of sequential versus concurrent G3139 administration on survival in a lymphoma-bearing
SCID mouse model.
Blood.
2004;
104
(Suppl 1)
392a
- 28
Rohatiner A, Davies A, Apostolidis J, Neuberg D, Matthews J, Nadler L, ALister A,
Freedmann A.
High dose therapy (HDT) with autologous haematopoietic progenitor cell support as
consolidation of remission in patients with follicular lymphoma (FL): Long follow-up
of St. Bartholomew’s Hospital (SBH) and Dana-Farber Cancer Institute (DFCI) data.
Ann Oncol.
2005;
16
v48
(Suppl 5)
- 29
Saleh M, Dakhil S, deVos S, Patel-Donnelly. et al .
Phase 2 study of Bortezomib and rituximab in patients with indolent non-Hdogkin’s
lymphoma (NHL).
Ann Oncol.
2005;
16
v136
(Suppl 5)
- 30
Salles G, Foussard C, Nicolas M. et al .
Rituximab Added to aIFN+CHVP Improves the Outcome of Follicular Lymphoma Patients
with a High Tumor Burden: First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial
in 359 Patients.
Blood.
2004;
104
(Suppl 1)
160a
- 31
Schouten H C, Qian W, Kvaloy S. et al .
High-dose therapy improves progression-free survival and survival in relapsed follicular
non-Hodgkin’s lymphoma: results from the randomized European CUP trial.
J Clin Oncol.
2003;
1
918-927
- 32
Sebban C, Belanger C, Brousse N. et al .
Comparison of CHVP + Interferon with CHOP Followed by Autologous Stem Cell Transplantation
with a TBI Conditioning Regimen in Untreated Patients with High Tumor Burden Follicular
Lymphoma: Results of the Randomized GELF94 Trial (GELA Study Group).
Blood.
2003;
102
(Suppl 1)
54a
- 33
Solal-Celigny P, Roy P, Colombat P. et al .
Follicular Lymphoma International Prognostic Index.
Blood.
2004;
104
1258-1265
- 34
Van Besien K, Loberiza F R, Bajorunaite R. et al .
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for
follicular lymphoma.
Blood.
2003;
102
3521-3599
- 35
Weng W K, Czerwinski D, Timmerman J. et al .
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with
humoral immune response and immunoglobulin G Fc receptor genotype.
J Clin Oncol.
2004;
22
4717-4724
- 36 Winter J N. Controversies in the treatment of follicular lymphomas (grades 1 and
2). In: Heamatology 2004_ASH Educational Book 2004: 208-211
- 37
Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C. et al .
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy
versus rituximab immunotherapy for patients with relapsed or refractory low-grade,
follicular, or transformed B-cell non-Hodgkin’s lymphoma.
J Clin Oncol.
2002;
20
2453-2463
Priv.-Doz. Dr. M. Dreyling
Klinikum Großhadern der Universität München, Medizinische Klinik III
Marchioninistr. 15
81377 München
Phone: 089/70952202
Fax: 089/70952201
Email: Martin.Dreyling@med.uni-muenchen.de
